Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.

Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, Waheed S, Shaughnessy JD Jr, Alsayed Y, Heuck CJ, van Rhee F, Milner T, Hoering A, Szymonifka J, Sexton R, Sawyer J, Singh Z, Crowley J, Barlogie B.

Leukemia. 2012 Nov;26(11):2398-405. doi: 10.1038/leu.2012.107. Epub 2012 Apr 17.

2.

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M.

Blood. 2011 Dec 1;118(23):5989-95. doi: 10.1182/blood-2011-06-361386. Epub 2011 Sep 6. Erratum in: Blood. 2012 Sep 13;120(11):2349.

3.

Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.

Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R.

J Clin Oncol. 2011 Oct 1;29(28):3805-12. doi: 10.1200/JCO.2011.34.9290. Epub 2011 Sep 6. Review.

PMID:
21900099
4.

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, Sureda A, de la Rubia J, Conde E, Martinez R, de Arriba F, Viguria MC, Besalduch J, Cabrera R, Gonzalez-San Miguel JD, Guzman-Zamudio JL, Gomez del Castillo MC, Moraleda JM, García-Ruiz JC, San Miguel J, Lahuerta JJ; Grupo Español de MM; Programa para el Estudio de la Terapé utica en Hemopatía Maligna.

Blood. 2011 Jul 21;118(3):529-34. doi: 10.1182/blood-2011-01-332320. Epub 2011 Apr 11.

5.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group.

Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. Review.

PMID:
20410922
6.

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL.

J Clin Oncol. 2010 Mar 1;28(7):1209-14. doi: 10.1200/JCO.2009.25.6081. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

7.

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.

Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, Garderet L, Belhadj K, Dorvaux V, Minvielle S, Moreau P; IFM and MAG groups.

Leukemia. 2010 Mar;24(3):623-8. doi: 10.1038/leu.2009.273. Epub 2010 Jan 14.

PMID:
20072152
8.

P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.

López-Anglada L, Gutiérrez NC, García JL, Mateos MV, Flores T, San Miguel JF.

Eur J Haematol. 2010 Apr;84(4):359-61. doi: 10.1111/j.1600-0609.2009.01399.x. Epub 2009 Dec 14.

PMID:
20002730
9.

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Zhou Y, Barlogie B, Shaughnessy JD Jr.

Leukemia. 2009 Nov;23(11):1941-56. doi: 10.1038/leu.2009.160. Epub 2009 Aug 6. Review.

10.

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients.

Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M.

Ann Oncol. 2010 Feb;21(2):325-30. doi: 10.1093/annonc/mdp329. Epub 2009 Jul 24.

PMID:
19633044
11.

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B.

Blood. 2009 Sep 3;114(10):2068-76. doi: 10.1182/blood-2009-03-213280. Epub 2009 May 14.

12.

The impact of extramedullary disease at presentation on the outcome of myeloma.

Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, Shaw BE, Morgan GJ.

Leuk Lymphoma. 2009 Feb;50(2):230-5. doi: 10.1080/10428190802657751.

PMID:
19197724
13.

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV.

Blood. 2009 May 28;113(22):5412-7. doi: 10.1182/blood-2008-12-194241. Epub 2009 Jan 29.

14.

'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring.

Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R, Engelhardt M.

J Cancer Res Clin Oncol. 2009 Mar;135(3):477-84. doi: 10.1007/s00432-008-0470-7. Epub 2008 Sep 18.

PMID:
18802723
15.

Improved survival in multiple myeloma and the impact of novel therapies.

Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA.

Blood. 2008 Mar 1;111(5):2516-20. Epub 2007 Nov 1.

16.

Clinical implication of centrosome amplification in plasma cell neoplasm.

Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R.

Blood. 2006 May 1;107(9):3669-75. Epub 2005 Dec 22.

17.

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S, Paternoster S, Adeyinka A, Ketterling R, Van Dyke DL, Fonseca R, Kyle R.

Blood. 2005 Nov 15;106(10):3553-8. Epub 2005 Jul 19.

18.
19.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr.

Blood. 2002 Mar 1;99(5):1745-57.

20.

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd.

N Engl J Med. 2002 Feb 21;346(8):564-9.

Supplemental Content

Support Center